Premarin 0.625mg tablet is an hormone replacement therapy contains the active ingredient Conjugate Estrogen. It is an a female sex hormone that belongs to the family known as estrogens. It is used to treat menopausal symptoms in and around the vagina (such as itching, dryness, burning, and pain). It is used to treat painful intercourse caused by menopausal changes of the vagina.
Do not take Premarin 0.625mg tablet if you are allergic to Conjugate Estrogen, or any of its ingredients. Do not initiate the use of this medicine if you experience unusual vaginal bleeding, have a history of certain cancers, including breast or uterine cancer, have had a stroke or heart attack, suffer from blood clot issues, have liver problems, a diagnosed bleeding disorder. Consult your healthcare provider if you have or have had cancer before considering the use of this medicine. If you suspect pregnancy, avoid using the tablet.
Inform your doctor about any unusual vaginal bleeding, as postmenopausal vaginal bleeding could indicate uterine cancer. Share your complete medical history, especially conditions like asthma, epilepsy, diabetes, migraine, endometriosis, lupus, heart, liver, thyroid, kidney issues, or elevated blood calcium levels. Disclose all medications, including prescriptions, non-prescriptions, vitamins, and herbs, as interactions with Premarin 0.625mg tablet are possible. If you are planning for surgery or bedrest, consult your healthcare provider, and if breastfeeding, be aware that the tablet's estrogen hormones may pass into breast milk. Also, notify your physician about any gallbladder disease risk, as estrogens can elevate this risk. Discontinue estrogen use if severe hypercalcemia, vision loss, extreme hypertriglyceridemia, or cholestatic jaundice arises. For women on thyroid replacement therapy, closely monitor thyroid function.
Qianyiastrozin Tablets (Conjugate Estrogen)Before starting treatment with Premarin 0.625mg tablet, tell your healthcare provider of any medical conditions you may have, such as liver disease, heart problems, thyroid problems, diabetes, or seizures. Your healthcare provider should discuss potential risks and benefits of using this medicine with you, especially if you have a history of heart problems or stroke. If you experience symptoms of heart problems or stroke, such as changes in vision or blood pressure, sudden numbness or weakness, or tingling or burning sensations, promptly contact your healthcare provider for immediate medical attention.
Premarin 0.625mg tablet can interact with certain medications, including certain anti-cholesterol medications, certain antidepressants, certain immunosuppressants, and medications for blood clotting disorders. Specifically, certain drugs used to treat high cholesterol, such as fluconazole, have been linked to the occurrence of breast cancer in some individuals. Therefore, it is crucial to inform your healthcare provider about all medications you are taking before starting treatment with Premarin 0.625mg tablet. Also, inform your healthcare provider if you are currently pregnant, plan to become pregnant, or are breastfeeding before taking Premarin 0.625mg tablet. Inform your healthcare provider if you are currently taking any of the following medications: warfarin, insulin, phenytoin, or clopidogrel; or are taking any other medications regularly: warfarin, digoxin, digoxin or other anticoagulants (type I anticoagulants); insulin, digoxin, digoxin or other antacids; oral contraceptives, or estrogen-containing birth control; or other medications for hormone-sensitive cancers, including tamoxifen, dihydrotestosterone (DHT), or levonorgestrel.
Premarin 0.625mg tablet may interact with certain medications, including certain anti-cholesterol medications, certain antidepressants, certain immunosuppressants, and medications for blood clotting disorders. Also, inform your healthcare provider if you are currently taking any regularly: certain antacids (like magnesium or aluminum), tamoxifen; or other medications for hormone-sensitive cancers, including tamoxifen, dihydrotestosterone (DHT), or levonorgestrel.
Store Premarin 0.625mg tablet at room temperature away from moisture and heat. Do not allow the tablet to freeze. Keep Premarin 0.625mg tablet out of the reach of children and pets. Before using Premarin 0.
What PREMARIN VAGINAL is used for?
PREMARIN VAGINAL is used to manage vaginal itching, inflammation, dryness, and vaginal thinning caused due to estrogen deficiency (atrophic vaginitis). It can also be used to manage itching and inflammation of vulva and other parts of the genital area such as labia minora, clitoris and vaginal orifice (kraurosis vulvae). It also helps in manageing moderate to severe dyspareunia (genital pain during sexual intercourse) that occurs due to menopause.
Who should not use PREMARIN VAGINAL?
PREMARIN VAGINAL is not recommended for use in patients allergic to Conjugated estrogens. It is also not suitable for use in patients having unusual vaginal bleeding, breast or uterine cancer, blood clot in legs (deep venous thrombosis) or lungs (pulmonary embolism), bleeding disorder or heart problems. PREMARIN VAGINAL should not be used in pregnant or breastfeeding without consulting your doctor.
How to use PREMARIN VAGINAL?
Apply PREMARIN VAGINAL as directed by your physician. It should be used only in and around the vagina or the genital area. PREMARIN VAGINAL comes in a tube along with an applicator. Use the applicator for applying the medicine. Gently squeeze the sufficient medicine from the tube into the applicator. Lie down on your back or in any comfortable position. Gently insert the applicator into the vagina and press the plunger downwards to release the medicine in the vagina. Remove the applicator from the vagina after application. If you want to apply PREMARIN VAGINAL to the external parts of vagina, take the required quantity of PREMARIN VAGINAL and apply it at the required sites of the genital area.
What are the side effects of PREMARIN VAGINAL?
The most common side effects of applying PREMARIN VAGINAL are stomach pain, back pain, breast pain or tenderness, headache, vaginal infection, or vaginal discharge. Consult your doctor if any of these side effect worsens. Also, inform your doctor if you experience any changes in your breast such as breast pain, tenderness, discharge from the nipple, or lump growth in the breasts, heavy menstrual bleeding, pain, swelling, redness of the legs, sudden chest pain or difficulty in breathing after using PREMARIN VAGINAL.
Can PREMARIN VAGINAL cause cancer?
Yes. Research has that shown that prolonged use of PREMARIN VAGINAL may lead to breast cancer or uterine cancer. To avoid this, your doctor will constantly monitor your health condition through periodic blood tests and ultrasounds (breast examination). However, inform your doctor immediately if you experience any unusual symptoms such as severe breast pain or tenderness, purplish discoloration of breasts, discharge from nipples, pelvic pain or abnormal vaginal bleeding.
xiety orWhat are the side effects of taking PREMARIN VAGINAL as prescribed?
The most common side effects of taking PREMARIN VAGINAL as prescribed are stomach pain, back pain, breast pain or tenderness, headache, vaginal infection, or vaginal discharge.
foreseenApply plain oral remembering the prescribed dose is important for long-term management of symptoms of vaginal or oral bleeding, dizziness, and gynecomastia. Using PREMARIN VAGINAL in longer term management has shown to lower this risk. Pfizer, the pharmaceutical company that generated the medicine, was quoted as a driving force in the development of the treatment.
Postmenopausal women with pre-menopausal hormone therapy may be at an increased risk of developing breast cancer. This risk appears to be increased in women with advanced breast cancer and is particularly high in women aged 50–64 years. The risk of breast cancer increases in the presence of advanced hormone therapy and can increase in the presence of other hormone-dependent cancers.
In this context, the aim of the present work was to analyze the effects of hormone therapy in postmenopausal women with breast cancer, and to compare the outcomes with that of pre-menopausal women without breast cancer, as well as to evaluate the risk of breast cancer in those patients.
We retrospectively studied 4,927 women between 18 and 55 years with breast cancer between 2001 and 2010. The patients were treated with pre-menopausal hormone therapy (Premarin or Premarin ER). The study was approved by the ethical committee of the Faculty of Medicine, University of Huddersfield, and the protocol was carried out in accordance with the Helsinki Declaration of 1964. All patients provided written informed consent. The study was registered in the UK Clinical Trial Registry and the Danish Registry for the Evaluation of Breast Cancer. The study was conducted in accordance with the recommendations of the International Society for the Study of Ovarian Oncology (ISSOC) ().
Breast cancer was diagnosed by a physician-directed examination. The diagnostic laboratory of the patients was performed according to the diagnostic procedure of the American Society of the Gynecology (ASRM). The main diagnostic procedure was an endometrial biopsy, which was performed by a physician, who also performed a mammogram and a biopsy of the breast, as well as by a laboratory in the same clinic. The diagnostic laboratory of the patients was the same as for the patients in the premenopausal group. The primary cancer was diagnosed on the basis of an endometrial biopsy performed by a physician.
The endometrial biopsies were performed by a physician, who also performed a mammogram and a biopsy of the breast, as well as by a laboratory in the same clinic. A laboratory diagnosis of breast cancer was made according to the American Society of the Gynecology (ASRM) diagnostic criteria. The diagnostic laboratory was in the same clinic as in the premenopausal group. The diagnostic laboratory was not performed in any other clinic at the time of the biopsy. The diagnostic laboratory was not used in the final analysis of the study.
The rates of breast cancer in the women were obtained by applying the following definitions: a) the prevalence of breast cancer; b) the number of cases of breast cancer; and c) the number of cases of breast cancer in each group of women who were evaluated in the same group. The prevalence of breast cancer in the women who received hormone therapy was reported as the ratio of incidence of breast cancer in the women who received hormone therapy.
The incidence rate was determined by dividing the number of cases of breast cancer by the total number of cases. The incidence rate in women who received hormone therapy was also determined as the ratio of the cumulative number of cases of breast cancer to the cumulative number of cases in the woman who received hormone therapy.
The prevalence of breast cancer was determined using the following definitions: a) the prevalence of breast cancer; b) the number of cases of breast cancer; and c) the number of cases of breast cancer in each group of women who were evaluated in the same group. The prevalence of breast cancer in the women who received hormone therapy was reported as the ratio of the cumulative number of cases of breast cancer to the cumulative number of cases in the woman who received hormone therapy.
The outcomes of the study were evaluated according to the following definitions: a) the number of cases of breast cancer; b) the number of cases of breast cancer; and c) the number of cases of breast cancer in each group of women who were evaluated in the same group.
The Premarin Vaginal Cream is a topical cream that is applied directly to the vaginal area. Premarin Vaginal Cream is a prescription-only drug and should only be used by women who are experiencing symptoms of menopause such as vaginal dryness or itching. Premarin Vaginal Cream is typically applied to the vagina for five days before intercourse. It is important to consult a healthcare professional before using Premarin Vaginal Cream to ensure that it is appropriate for the individual patient.
It is not recommended to use Premarin Vaginal Cream if you are pregnant or breastfeeding. Premarin Vaginal Cream should not be used during pregnancy unless it is necessary. It is not recommended to use Premarin Vaginal Cream if you are currently breastfeeding.
Before taking Premarin Vaginal Cream, it is important to inform your doctor about any pre-existing medical conditions, including:
It is not recommended to use Premarin Vaginal Cream if you are currently pregnant unless necessary.
VIDEO
Stade de France Pharmacy